Gal Markel

This inventor holds 9 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 7 EPO patents. Top assignees: Famewave Ltd., Tel Aviv University, Tel Hashomer Medical Research Infrastructure and Services Ltd.. Active years: 2013-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gal Markel. Retrieved from https://idiyas.com/inventor/gal-markel-a7vxjv2i

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 9)

% Patents Active = 77.8

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 11)

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 20(Granted Patents)

Location History:

Tel Aviv, IL (2013 - 2024)
Ramat Gan, IL (2020 - 2024)

Company Filing History:

Tel Hashomer Medical Research Infrastructure and Services Ltd.

patents

4. 1 out of 2

Ccam Biotherapeutics Ltd.

patents

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11891453 - Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM) (2024-02-06),

2. 11866509 - Humanized antibodies against CEACAM1 (2024-01-09),

3. 11427647 - Polynucleotides encoding humanized antibodies against CEACAM1 (2022-08-30),

4. 10550196 - Humanized antibodies against CEACAM1 (2020-02-04),

5. 9771431 - Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM) (2017-09-26),

6. 9261507 - Anti CEACAM1 antibodies and methods of using same (2016-02-16),

7. 9238838 - Microrna patterns for the diagnosis, prognosis and treatment of melanoma (2016-01-19),

8. 8980549 - MicroRNA patterns for the diagnosis, prognosis and treatment of melanoma (2015-03-17),

9. 8598322 - Anti CEACAM1 antibodies and methods of using same (2013-12-03),

Title: Gal Markel: Innovator in Antibody Development

Introduction

Gal Markel is a prominent inventor based in Tel Aviv, Israel, known for his significant contributions to the field of biotechnology. With a total of nine patents to his name, he has made remarkable advancements in the development of antibodies for therapeutic and diagnostic purposes.

Latest Patents

Among his latest patents, Markel has developed antibodies targeting the carcinoembryonic antigen-related cell adhesion molecule (CEACAM). This invention provides antibodies that recognize a specific epitope of the CEACAM1 protein and may also bind to other subtypes of the CEACAM protein family. The disclosed antibodies and antibody fragments are characterized by specific CDR sequences, along with methods for their production and use in therapy and diagnosis. Another notable patent involves humanized antibodies against CEACAM1, which are capable of specific binding to human CEACAM1 molecules. These antibodies contain human-to-murine back-mutations in non-CDR variable regions, and the patent also includes their encoding polynucleotide sequences. Pharmaceutical compositions comprising these antibodies, as well as methods for their use in treating and diagnosing cancer and other conditions, are also provided.

Career Highlights

Throughout his career, Gal Markel has worked with notable organizations, including Tel Hashomer Medical Research Infrastructure and Services Ltd. and Ramot at Tel Aviv University Ltd. His work in these institutions has contributed to the advancement of medical research and innovation.

Collaborations

Markel has collaborated with esteemed colleagues such as Jacob Schachter and Rona Ortenberg, further enhancing the impact of his research and inventions.

Conclusion

Gal Markel's innovative work in antibody development has positioned him as a key figure in biotechnology. His contributions continue to influence the fields of cancer treatment and diagnostics, showcasing the importance of his inventions in modern medicine.

Profile summary based on public USPTO records.